Preparation method for Mitiglinide calcium

A mitiglinide calcium and action technology, which is applied in the preparation field of mitiglinide calcium to achieve the effects of reducing environmental pollution, friendly reaction conditions and high yield
CN102898348AInactive Publication Date: 2013-01-30DISHA PHARMA GRP +1
5 Cites 7 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
DISHA PHARMA GRP
Publication Date
2013-01-30
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a preparation method for a bulk drug, i.e., Mitiglinide calcium, used for treating type II diabetes mellitus. According to the invention, improvement of the prior art is carried out: sodium methoxide is used to replace metallic sodium in the prior art, so reaction conditions are friendlier, and industrial production is easier to operate; the usage amount of benzaldehyde is reduced and argon protection is avoided, so environmental protection is benefited, and reaction yield is increased; and the usage amount of a palladium carbon (Pd / C) catalyst is reduced, which enables environmental pollution caused by excess usage of the heavy metal palladium to be reduced and cost to be lowered down.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Technical field The present invention relates to a preparation method of mitiglinide calcium raw material medicine for treating type II diabetes. Background technique

[0002] Miglinide calcium, Chinese chemical name: (+)-bis[(2S)-2-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)butyrate]calcium. This product can be used alone for patients with type II diabetes whose hyperglycemia cannot be effectively controlled by diet and exercise therapy. Miglitide calcium is the third meglitide drug after repaglinide and nateglinide, and it is a derivative of phenylalanine.

[0003] The compound was synthesized by Japan Tachibana Pharmaceutical Co., Ltd., and was applied for in December 2002 to control postprandial blood sugar in patients with type II diabetes, and was launched in Japan in April 2004.

[0004] Chinese patents with application numbers 20061011970.7, 200710064579.8, 201010573659.8, 201010573666.8, 201110344642.X and other Chinese patents disclose the preparation methods ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More